2/4/2017 Update: Jeanmarie Guenot’s subsidiary Maverick Therapeutics has just agreed a new partnership with Takeda. This will see both companies work together on a new form of T-Cell engagement therapies. The move will use the latest medical advancements from both companies, and combine them into one new program, to develop new and innovative cancer treatments. This is just the latest in Jeanmarie Guenot’s hard work towards cancer therapy, and ultimately a cure.

JeanMarie Guenot, Ph.D. is the CEO and President of Amphivena Therapeutics, Inc., an innovative firm in the health sector. The company manufactures cancer immune therapeutics. JeanMarie has over two decades of pharmaceutical and biotechnological experience in different establishments.


GuenotLLC.com reveals that JeanMarie trained in Physical and Medicinal Chemistry and attained her Ph.D. from the University of California and her MBA from Wharton School at the University of Pennsylvania.


Dr. JeanMarie Guenot began her career in business at Atlas Venture, from she established life science companies and managed venture capital investments. Her scientific career kicked off at Hoffmann-La Roche as a scientist in Preclinical R&D.


She has worked in private and public companies, pharmaceutical R&D, business development, project and alliance management, corporate and commercial development, and in venture capital.


Dr. Jeanmarie established and managed an ophthalmic company called SKS Ocular. She emphasized on dry AMD and released therapeutics and technologies for dealing with glaucoma, ocular inflammation and macular degeneration.


She was a financial advisor at Hoffman-La Roche in Shanghai and Basel. She also served as the Vice President of Corporate and Business Development for PDL BioPharma. In this company, she was responsible for licensing, mergers and management of alliances for R&D and PDL’s product portfolio.


She negotiated the 50:50 PDL-Biogen Idec collaboration deal on co-commercialization and co-development which involved cancer and autoimmune drug candidates. This transaction was worth $800 million. Later, she licensed an ophthalmic indication for oncology drug to Ophthotech Corporation.


JeanMarie is well versed in oncology, autoimmunity, neurology, cardiovascular disorders and ophthalmic diseases.


The 2015 Cancer Immunotherapy Development Milestones


In early 2015, Amphivena Therapeutics, Inc., and Janssen Biotech, Inc. came into a binding agreement where they picked a clinical candidate to investigate an undisclosed tumor antigen, under the leadership of Dr. Jeanmarie Guenot. The aim was to advance the development of solutions to hematologic malignancies.


As a result, Amphivena received payments for the first and second milestones. Johnson and Johnson Innovation facilitated the agreement.


JeanMarie expressed her gratitude for the milestones saying that they achieved them much earlier than they anticipated. She said the company would now be able to advance their candidate to the clinic rapidly to save the lives of people in danger due to various cancers.  For more about this talented doctor and entrepreneur, visit Jeanmarie’s website.


Leave a Reply

Post Navigation